Kyalin Biosciences - Ownership and Business Overview

Life ScienceCompany

Kyalin Biosciences Ownership

Who owns Kyalin Biosciences?

Kyalin Biosciences is owned by Travere Therapeutics. It was acquired on December 12, 2013.

Kyalin Biosciences Business Overview

Where is Kyalin Biosciences headquartered?

Kyalin Biosciences is headquartered in Encinitas, California.

What sector is Kyalin Biosciences in?

Kyalin Biosciences is a life science company.

Life Science M&A Summary in 2013

Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2013. The largest life science acquisition in 2013 was Onyx Pharmaceuticals - which was acquired by Amgen for $10.4B.

Join Mergr to view all 191 acquisitions of life science companies in 2013, including 25 acquisitions by private equity firms, and 166 by strategics.

Kyalin Biosciences, Inc.

1477 Paseo de las Flores,
Encinitas, California 92024
United States,
(858) 779-4253
www.kyalinbio.com

Kyalin Biosciences, Inc. is an early-stage company, that is developing therapies targeting the core symptoms of autism and related conditions. Its lead product is an optimized intranasal delivery form of carbetocin, a synthetic analog of the naturally occurring peptide hormone, oxytocin. Kyalin Biosciences develops therapies targeting the core symptoms of autism and related conditions. While autism affects 1 in 88 children in the U.S.


 Subscribe to unlock this and 202,314
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 194K M&A Transactions
  • 198K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.